The KRAS Mutation is Highly Correlated With EGFR Alterations in Patients With Non-small Cell Lung Cancer
Received 1 October 2009; received in revised form 26 October 2009; accepted 30 October 2009.
To understand epidermal growth factor receptor (EGFR) and KRAS alterations among tissues of lung cancer patients in Taiwan, and to further understand how they are related, we used tumor tissues from the non-small cell lung cancer patients and performed a complete analysis. In the experimental results, coexisting EGFR and KRAS mutations were found in 1% (2/180) of the samples. This shows that these mutations tend not to coexist. Furthermore, nearly no coexistence was found between KRAS mutations and EGFR overexpression. These outcomes greatly assist the efficacy prediction of current anti-EGFR drugs for cancer patients.
iDepartment of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Corresponding authors. Jaw-Yuan Wang: Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Tzyou 1st Road, Kaohsiung 807, Taiwan. Shiu-Ru Lin: School of Medical and Health Sciences, Fooyin University, 151 Chin-Hsueh Road, Ta-Liao Hsiang, Kaohsiung 831, Taiwan
† Ming-Je Yang and Chi-Kuei Hsu contributed equally to this work.